HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FiberChoice recall

This article was originally published in The Tan Sheet

Executive Summary

GlaxoSmithKline announces March 20 it is recalling 144,000 bottles of FiberChoice Plus Multivitamins because fish gelatin, a known allergen, was not declared on the label. The recall affects 90-count, 16 oz. bottles that began shipping to retailers Jan. 15. No reports of adverse reactions had been reported as of the recall announcement. The Food Allergen Labeling Consumer Protection Act of 2004 requires that manufacturers of dietary supplements disclose major food allergens on product labeling (1"The Tan Sheet" Oct. 24, 2005, p. 10). GSK completed its acquisition of FiberChoice manufacturer CNS in December 2006 (2"The Tan Sheet" Jan. 1, 2007, In Brief)...

You may also be interested in...



FDA Guidance Clarifies Labeling For Supplements Containing Food Allergens

Manufacturers of dietary supplements are required to begin labeling products that contain major food allergens on Jan. 1 in order to comply with the Food Allergen Labeling & Consumer Protection Act of 2004 (FALCPA)

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS138874

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel